Tm Bioscience Approves More Stock Options | GenomeWeb

TORONTO--Tm Bioscience here, which designs, develops, and commercializes DNA products for bioinformatics, functional genomics, and other uses, has auth orized the issuance of an additional 340,000 stock purchase op tions, subject to approval by the Vancouver Stock Exchange. The options vest over four years and expire on August 26, 2001. They have been awarded to recently appointed executives and employees.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.